Navigation Links
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
Date:11/20/2007

over 12.5 million prescriptions have been written for ABILIFY in the U.S.(10) through June 2007.

ABILIFY is available by prescription only. ABILIFY Tablets should be taken once daily with or without food and are available in 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg strengths. As adjunctive treatment to antidepressant therapy in adults with major depressive disorder, ABILIFY Oral starting dose is 2 mg/day to 5 mg/day with a maximum dose of 15 mg/day. Dose adjustments of up to 5 mg/day should occur gradually, at intervals of no less than one week.

IMPORTANT SAFETY INFORMATION and INDICATIONS for ABILIFY

INDICATIONS:

-- ABILIFY is indicated for use as an adjunctive treatment to

antidepressants for major depressive disorder in adults.

IMPORTANT SAFETY INFORMATION:

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. ABILIFY is not approved for the treatment of patients with dementia-related psychosis (see Boxed WARNING).

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD). Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior, especially during the initial few months of therapy, or at times of dose changes. ABILIFY is not approved for use in pediatric patients with depression (See Boxed WARNING).

Cerebrovascular adverse events (eg, stroke, transient ischemic attack),

including fatalities, have been reported at an increased incidence in

clinical trials of elderly patients with dementia-related psychosis

treated with ABILIFY

Neuroleptic malignant syndrome (NMS)-As with all antipsychotic

medications, a rare and pot
'/>"/>

SOURCE Bristol-Myers Squibb Company and Otsuka PharmaceuticalCo., Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Bioscrypts V-Station MIFARE Placed on Transportation Security Administrations Qualified Products List
3. Australian Therapeutics Goods Administration Approval for ActiPatch Achieved
4. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
5. Korean Food and Drug Administration Approval for ActiPatch Achieved
6. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
7. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
8. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
9. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
10. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
11. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015 According ... Market by Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), ... Labs, Research Institutes) - Analysis & Global Forecast ... the global Antibody Production Market for the forecast ... expected to reach $2.572 Billion by 2019 from ...
(Date:4/30/2015)... 2015 Spirax Sarco, the leader in ... to announce that for the first time in the ... of a Queen’s Award for Innovation – the UK’s ... manufacture of a unique flowmeter. , The Spirax Sarco ... traditional steam flow measurement. The device provides reliable, ...
(Date:4/30/2015)... , April 30, 2015   Tamir Biotechnology ... today an update on its Ebola antiviral therapy program. ... leading candidates, TMR004, is currently being evaluated and considered ... the battle against Ebola. During the first quarter of ... Leadership Meeting To Accelerate The Evaluation of Potential Treatments ...
(Date:4/30/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), an ... has commenced an underwritten public offering of its common ... a 30-day option to purchase up to an additional ... in the public offering. The offering is subject to ... to whether or when the offering may be completed, ...
Breaking Biology Technology:Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3
... April 1, NovaBay Pharmaceuticals, Inc. (NYSE Amex: ... developing first-in-class anti-infective products for the treatment and ... causing resistance, reported today its financial results for ... 31, 2008. The company also announced clinical ...
... Submits Contract Proposal to Further Develop Environmental Biosensor ... Biomedical, Inc., a leader in human embryonic stem ... submitted a Department of Defense contract proposal to ... cell technology. (Logo: ...
... 1 /PRNewswire-Asia-FirstCall/ -- Yongye Biotechnology,International, Inc. (OTC Bulletin ... of nutrients for plants and animals, located in ... named Mr. Sam Yu to be the,Company,s new ... Mr. Yu,replaces Larry Gilmore, who served as the ...
Cached Biology Technology:NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 2NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 3NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 4NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 5NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 6NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 7NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 8NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 9ArunA Biomedical Submits Contract Proposal to Further Develop Environmental Biosensor for National Security 2Yongye Biotechnology Appoints New Chief Financial Officer 2Yongye Biotechnology Appoints New Chief Financial Officer 3
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
(Date:4/13/2015)... , April 13, 2015  higi, a leading ... ways to more fully engage with their communities around ... industry-leading, privacy protected and secure API.  ... enables the most accessible, affordable, and convenient vehicle to ... The API will allow ...
(Date:4/8/2015)... CHARLOTTE, N.C. , April 8, 2015 /PRNewswire/ ... technology solutions and services, and Morpho, a leading ... in partnership to produce the market,s most advanced ... Infinisource,s iSolved NXG time clock is setting ... attendance and labor data for the small and ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... A new study provides support for Darwin,s ... between more closely related species than those distantly ... new study contains the strongest direct experimental evidence ... that species extinction occurred more frequently and more ...
... a better state to recall where you put them at some ... A paper describing the work is published June 13 in the ... "It,s been assumed that the process of retrieving a memory is ... UC Davis Center for Neuroscience and Department of Psychology. "But we ...
... intimate and complex relationship between inflammation and cancer; and it ... attract host cells which drive inflammation and help to support ... Press in the June issue of the journal Cancer ... trafficking of immune cells involved in inflammation. The research ...
Cached Biology News:New study supports Darwin's hypothesis on competition between species 2New study supports Darwin's hypothesis on competition between species 3Brain state affects memory recall 2Blocking common gateway to inflammation suppresses cancer 2
MAb to Desmoplakin I & II Desmoplakin I & II...
BD Biocoat Matrigel Matrix Thin Layer 35 mm Culture Dishes...
... Activation of ICE-family proteases/caspases initiates apoptosis in ... Apoptosis Detection Kit provides a simple and ... by flow cytometry in intact cells. ... two aspartate residues linked to rhodamine 110 ...
... pLivSelect is a direct antibiotic-based selection system ... on colony survival, eliminating the need for ... process provides close to 100% accuracy in ... platform for robot colony picking. This cloning ...
Biology Products: